News from rhovac A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 07, 2021, 09:21 ET First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom

RhoVac AB ("RhoVac") announces today, on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company's clinical phase IIb...


Nov 25, 2020, 02:56 ET RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the company's drug candidate, RV001....


Nov 13, 2020, 03:47 ET Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer

RhoVac announces today, November 13, 2020, that the results of its clinical phase I/II study have been published in the Journal for ImmunoTherapy of...


Oct 26, 2020, 03:52 ET RhoVac Participates in BIO Europe Digital

RhoVac AB ("RhoVac") announces today that it is participating this week in the partnering event BIO Europe 2020 Digital. This week the digital...


Oct 26, 2020, 03:44 ET Article on RhoVac's Phase I/II study to be published in November

RhoVac AB ("RhoVac") announces today that the publication of the article on RhoVac's Phase I/II study is set to be published in November. As...


Oct 12, 2020, 02:52 ET The Covid-19 pandemic is expected to further affect RhoVac's clinical phase IIb study

RhoVac AB ("RhoVac") announces today that the company's clinical phase IIb study in prostate cancer, a multi-center study with the designation...


Sep 17, 2020, 10:10 ET First patient in treatment in RhoVac's clinical phase IIb study in Sweden

RhoVac AB ("RhoVac") announces today, on September 17 2020, that the first patient in Sweden is enrolled in the company's clinical phase IIb study in ...


Sep 04, 2020, 05:23 ET RhoVac appoints Professor Georg Holländer to its Scientific Advisory Board

RhoVac AB ("RhoVac") announces today September 4th 2020, that it is continuing to strengthen the Scientific Advisory Board with a pediatric...


Aug 10, 2020, 03:55 ET First patient in treatment in RhoVac's clinical phase IIb study in the USA

The first patient in the USA is included in RhoVac's clinical phase IIb study, called BRaVac. The first US clinic to include a patient in the study...


Jul 01, 2020, 08:25 ET A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd

RhoVac AB ("RhoVac") is published in the June edition of MedNous, through a written commentary by CEO Anders Månsson. In order to further attract the ...


Jul 01, 2020, 03:34 ET RhoVac Marketed in International Press

RhoVac AB ("RhoVac") is marketed in the latest edition of the international trade press outlet, MedNous, through a written commentary by CEO Anders...


Apr 23, 2020, 11:54 ET First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany

RhoVac AB ("RhoVac") announces today, on 23rd April 2020, that the first patient in Germany is in treatment in the company's clinical phase IIb study ...


Apr 02, 2020, 05:08 ET Covid-19 Related Delays in the Ongoing Phase IIb-study are Expected to be Managed With Existing Funding

RhoVac AB ("RhoVac") announces today, on April 2 2020, that the company is now seeing signs of delays in the ongoing clinical phase IIb study with...


Mar 03, 2020, 08:24 ET First Patient in Treatment for RhoVac's Clinical Phase II Study in Finland

RhoVac AB ("RhoVac") announces today, on 3rd March 2020, that the first patient in Finland has started treatment in the company's clinical phase IIb...


Feb 06, 2020, 05:43 ET RhoVac Announces Appointment of Professor Anne J. Ridley to its Scientific Advisory Board

RhoVac AB ("RhoVac") announces today, 6th February 2020, the appointment of a leading oncology expert to its Scientific Advisory Board with the...


Jan 10, 2020, 07:20 ET RhoVac Receives Approval in Germany and Belgium to Start Clinical Phase IIb Study in Prostate Cancer

RhoVac AB ("RhoVac") announces today, on 10th January 2020, that the company has received approval from Beligian FAMHP (Federal Agency for Medicines...


Nov 18, 2019, 03:54 ET RhoVac Reports Interim Results on Immunological Response with RV001

Today, 18th November 2019, RhoVac AB ("RhoVac") reports interim results from ongoing immunological studies at University of Tübingen, Germany...


Nov 04, 2019, 01:50 ET First Patient Screened for RhoVac's Clinical Phase IIb-study

RhoVac AB ("RhoVac") announces today, on 4th November 2019, that the first patient has been screened for the company's clinical phase IIb study in...


Oct 30, 2019, 10:56 ET Gunnar Gårdemyr New Chairman of the Board of RhoVac

RhoVac AB ("RhoVac") announces today, 30th October 2019, that Mikael Ørum will leave the board and the chair of the board, Gunnar Gårdemyr, who was...


Oct 29, 2019, 04:30 ET RhoVac Receives Approval in Finland to Start Clinical Phase IIb Study in Prostate Cancer

RhoVac AB ("RhoVac") announces today, on 29th October, 2019, that the company has received approval from FIMEA (Finnish Medicines Agency) for...